The patent will be granted on May 2, 2023, and protecting AI based sophisticated, electronic health device SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”) announced that it received a noticed issue and will be granted on May 2, 2023, U.S. patent number 11,638,523, covering its machine learning-driven, human vitals device, non-provisional patent application, qTerm non-provisional patent was filed on August 3, 2020, describing an intelligent, electronic health device to measure human vitals with a touch of a finger, which was assigned qTerm as an internal project name. GBT successfully completed the development of a fully working prototype in 2022 including robust testing, debugging and a participant study. qTerm’s first release measures body temperature, blood oxygen and heart rate vitals. Future releases are planned to include blood pressure measurement and enhanced, AI-driven analytics. The device is accompanied by a smartphone mobile app and synchronized web application to keep measurement history and provide analytics for user's records at a later phase. The web and mobile applications also enable direct access to user’s data anywhere around the world, enabling efficient, remote telemedicine capabilities. Upon user’s permission, a user’s body temperature and location can be anonymously shared with other users to provide health risk proximity alerts. The patent describes advanced AI technology to perform on-going vitals monitoring and analytics, providing personal health related notifications and alerts. GBT plans to file a continuation patent for qTerm, further strengthening the underlying intellectual property concepts. For more information visit qTerm™ | Vital Signs Al Device. About Us GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services. Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. Contact: Dr. Danny Rittman, CTO [email protected] https://finance.yahoo.com/news/gbt-intelligent-human-vitals-qterm-113000405.html
